a549 human lung carcinoma epithelial cell line  (Procell Inc)

Journal: iScience

Article Title: Drug screening to identify compounds to eliminate Burkholderia pseudomallei through Hcp protein

doi: 10.1016/j.isci.2026.115367

Figure Lengend Snippet: Netilmicin sulfate alone and in combination exerted protective effects on an infected A549 cell model (A) Cytotoxic effects of the drugs on A549 cells. (B) Protective effects of different concentrations of NETS on A549 cells. The early interventions on the abscissa reflect the incubation of A549 cells with the drug for 2 h before B. pseudomallei HNBP001 infection. Late intervention was defined as the introduction of the drug to A549 cells 2 h after infection with B. pseudomallei HNBP001 . The ordinate is the survival rate of the infected A549 cells. NC: the blank negative control group of fresh 10% DMEM. Bp: infected A549 cell group. Bp+30 μM NETS: The infected A549 cells were treated with 30 μM NETS; the other conditions were the same, but different concentrations of NETS were used. (C) Protective effects of several drugs on infected A549 cells; the ordinate is the survival rate of infected A549 cells. NC, blank negative control group of fresh 10% DMEM. Bp: infected A549 cell group. Other: The infected A549 cells were treated with drugs (including SXT, GM, NETS, CAZ, and NETS+CAZ). (D) Number of intracellular bacteria in infected A549 cells after drug treatment; the ordinate represents the number of bacteria in infected A549 cells. NC is the blank negative control group of fresh 10% DMEM. Bp: infected A549 cell group. Drug group: 2 × MIC drug was used to treat infected A549 cells. All drugs, including SXT, GM, NETS, CAZ, and NETS+CAZ. (∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001; ns, no significant difference. Data are represented as mean ± SEM.).

Article Snippet: The A549 human lung carcinoma epithelial cell line was purchased from Procell (Wuhan, China; Cat# CL-0016).

Techniques: Infection, Incubation, Negative Control, Bacteria

Journal: iScience

Article Title: Drug screening to identify compounds to eliminate Burkholderia pseudomallei through Hcp protein

doi: 10.1016/j.isci.2026.115367

Figure Lengend Snippet: Netilmicin sulfate alone and in combination exerted protective effects on an infected A549 cell model (A) Cytotoxic effects of the drugs on A549 cells. (B) Protective effects of different concentrations of NETS on A549 cells. The early interventions on the abscissa reflect the incubation of A549 cells with the drug for 2 h before B. pseudomallei HNBP001 infection. Late intervention was defined as the introduction of the drug to A549 cells 2 h after infection with B. pseudomallei HNBP001 . The ordinate is the survival rate of the infected A549 cells. NC: the blank negative control group of fresh 10% DMEM. Bp: infected A549 cell group. Bp+30 μM NETS: The infected A549 cells were treated with 30 μM NETS; the other conditions were the same, but different concentrations of NETS were used. (C) Protective effects of several drugs on infected A549 cells; the ordinate is the survival rate of infected A549 cells. NC, blank negative control group of fresh 10% DMEM. Bp: infected A549 cell group. Other: The infected A549 cells were treated with drugs (including SXT, GM, NETS, CAZ, and NETS+CAZ). (D) Number of intracellular bacteria in infected A549 cells after drug treatment; the ordinate represents the number of bacteria in infected A549 cells. NC is the blank negative control group of fresh 10% DMEM. Bp: infected A549 cell group. Drug group: 2 × MIC drug was used to treat infected A549 cells. All drugs, including SXT, GM, NETS, CAZ, and NETS+CAZ. (∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001; ns, no significant difference. Data are represented as mean ± SEM.).

Article Snippet: A549 human lung carcinoma cell line , Procell , Cat#CL-0016.

Techniques: Infection, Incubation, Negative Control, Bacteria

Journal: Die Naturwissenschaften

Article Title: In vitro antiproliferative activity on A549 and HT-29 cell lines and fatty acid profiling of Agaricus bresadolanus and A. hortensis

doi: 10.1007/s00114-026-02089-0

Figure Lengend Snippet: The antiproliferative activity of the extract of A. bresadolanus on A549 lung cancer cells. Data points represent mean inhibition percentages. Error bars represent mean ± SD from three independent experiments. ( p < 0.01)

Article Snippet: The human lung carcinoma epithelial cell line A549 (ATCC, CCL-185TM), human colorectal adenocarcinoma cell line HT-29 (ATCC, HTB-38TM) and NIH/3T3 fibroblast (ATCC, CRL-1658TM) used in the current work were commercially available.

Techniques: Activity Assay, Inhibition

Journal: Die Naturwissenschaften

Article Title: In vitro antiproliferative activity on A549 and HT-29 cell lines and fatty acid profiling of Agaricus bresadolanus and A. hortensis

doi: 10.1007/s00114-026-02089-0

Figure Lengend Snippet: The antiproliferative activity of the extract of A. hortensis on A549 lung cancer cells. Data points represent mean inhibition percentages. The results given as mean ± SD from three independent experiments. ( p < 0.01)

Article Snippet: The human lung carcinoma epithelial cell line A549 (ATCC, CCL-185TM), human colorectal adenocarcinoma cell line HT-29 (ATCC, HTB-38TM) and NIH/3T3 fibroblast (ATCC, CRL-1658TM) used in the current work were commercially available.

Techniques: Activity Assay, Inhibition

Journal: bioRxiv

Article Title: The SF3B1 inhibitor pladienolide B massively inhibits DNA damage signaling and repair and counteracts resistance to platinum salts in Non-Small Cell Lung Cancer

doi: 10.64898/2026.02.17.706284

Figure Lengend Snippet: (a) Cell viability assay in cells treated or not for 72 hours with increasing concentrations of pladienolide B (nM). Mean ± SD. n = 3. (b) Quantification of apoptosis (%) by flow cytometry in cells treated with 5 nM pladienolide B for indicated times. Mean ± SD. n = 3. (c) Clonogenic assay in H460S/R cells treated or not for 14 days with 1 nM pladienolide B or 1 µM cisplatin. Lower panel: number of colonies with number in untreated condition being arbitrarily assigned to 100% survival. Mean ± SD. n = 3. (d) Spheroids from H460S/R cells treated with complete medium and DMSO as control, or 0.5 nM or 1 nM pladienolide B for the indicated days. Upper panels: representative images of spheroids at day 14. Lower panel: spheroids area (µm 2 ). Mean ± SD. n = 5 spheroids/condition. A representative experiment of 3 independent ones. (e) Representative immunoblots of SF3B1 in H460S/R or A549S/R cells. GAPDH was used as a loading control. n = 3. (f) H460R or A549R cells were transfected for 72 hours with a control siRNA or two distinct siRNA targeting Sf3b1 mRNA as indicated. Left panels: representative immunoblots of SF3B1. GAPDH was used as a loading control. Right panels: quantification of apoptosis (%). Mean ± SD. n = 3. (a, b, c, d, f) Unpaired t test. * p< 0.05, ** p< 0.01, *** p< 0.001, **** p< 0.0001, ns: not significant. (g) Overall Rate Response (ORR) at Day 20 for all NSCLC PDXs treated or not (control) with 2.5 mg/kg or 5 mg/kg pladienolide B (ip, Day 1-Day 4-Day 8-Day 11). Two-tails Mann-Whitney t test. ** p< 0.01. (h) Probability of progression (Relative Tumor Volume = 2) in control and pladienolide B-treated PDXs. n = 7 (LCIM1 is not included). Log-rank t test. ** p < 0.01.

Article Snippet: Human Non-Small Cell Lung Carcinoma (NSCLC) cell lines (H460, A549, H1299, H2170, H3255, H460, PC9, CALU-1, H1975, H226, H358, HCC827) were authenticated by DNA STR profiling (ATCC cell line Authentification Service, LGC standards, Molsheim, France) and routinely tested for mycoplasma contamination.

Techniques: Viability Assay, Flow Cytometry, Clonogenic Assay, Control, Western Blot, Transfection, MANN-WHITNEY

Journal: bioRxiv

Article Title: The SF3B1 inhibitor pladienolide B massively inhibits DNA damage signaling and repair and counteracts resistance to platinum salts in Non-Small Cell Lung Cancer

doi: 10.64898/2026.02.17.706284

Figure Lengend Snippet:

Article Snippet: Human Non-Small Cell Lung Carcinoma (NSCLC) cell lines (H460, A549, H1299, H2170, H3255, H460, PC9, CALU-1, H1975, H226, H358, HCC827) were authenticated by DNA STR profiling (ATCC cell line Authentification Service, LGC standards, Molsheim, France) and routinely tested for mycoplasma contamination.

Techniques: Inhibition, Mutagenesis

Journal: bioRxiv

Article Title: The SF3B1 inhibitor pladienolide B massively inhibits DNA damage signaling and repair and counteracts resistance to platinum salts in Non-Small Cell Lung Cancer

doi: 10.64898/2026.02.17.706284

Figure Lengend Snippet: (a, b) H460R or A549R cells were transfected for 72 hours with a control siRNA or two distinct siRNA targeting Sf3b1 mRNA as indicated. (a) Left panels: representative immunoblots of the indicated proteins. GAPDH was used as a loading control. Right panels: densitometric quantification (fold change) of SF3B1, ATR or DNA-PKcs signal normalized to GAPDH signal. Mean ± SD. n=3. (b) RT-qPCR (fold change) of SF3B1 , ATR or PRKDC mRNA level. Mean ± SD. n = 3. (a, b) Mann-Whitney t test. * p< 0.05, ** p< 0.01, *** p< 0.001, **** p<0.0001. (c) Correlation between SF3B1 and DNA-PKcs or ATR protein levels in a series of 77 NSCLC cell lines based on CCLE database. (d) Correlation between SF3B1 and PRKDC mRNA levels in lung adenocarcinoma patients retrieved from TCGA public database.

Article Snippet: Human Non-Small Cell Lung Carcinoma (NSCLC) cell lines (H460, A549, H1299, H2170, H3255, H460, PC9, CALU-1, H1975, H226, H358, HCC827) were authenticated by DNA STR profiling (ATCC cell line Authentification Service, LGC standards, Molsheim, France) and routinely tested for mycoplasma contamination.

Techniques: Transfection, Control, Western Blot, Quantitative RT-PCR, MANN-WHITNEY

Journal: bioRxiv

Article Title: The SF3B1 inhibitor pladienolide B massively inhibits DNA damage signaling and repair and counteracts resistance to platinum salts in Non-Small Cell Lung Cancer

doi: 10.64898/2026.02.17.706284

Figure Lengend Snippet: (a) Overall Rate Response (ORR) of all NSCLC PDXs (n = 25) treated with 4 mg/kg cisplatin, 5 mg/kg pladienolide B or a combination of both as compared to vehicle condition. Two-tails Mann-Whitney t test. ** p< 0.01, *** p< 0.001. (b) Probability of tumor progression (Relative Tumor Volume = 2) in control, pladienolide B-, cisplatin- or pladienolide B + cisplatin-treated PDXs. n = 7. Log-rank test. * p< 0.05, ** p < 0.01, *** p< 0.001. (c) LCF26 and ML1LC2 PDXs were treated with vehicle (ctrl), 4 mg/kg cisplatin, 5 mg/kg pladienolide B, or a combination of both. Left panels: immunoblots of DNA-PKCs and ATR. 3 PDXs/condition. GAPDH was used as a loading control. Right panels: normalized expression of DNA-PKcs or ATR according to GAPDH. Mann-Whitney t test. * p< 0.05, ** p< 0.01. (d) RT-PCR analysis of skipping of MLH3 -Ex8 in each PDX (3 distinct mice/PDX). Representative agarose gels of amplified products. Right numbers indicate amplicon size (in base pairs). Below numbers indicated the percentage of exon 8 exclusion. Mean ± SD.

Article Snippet: Human Non-Small Cell Lung Carcinoma (NSCLC) cell lines (H460, A549, H1299, H2170, H3255, H460, PC9, CALU-1, H1975, H226, H358, HCC827) were authenticated by DNA STR profiling (ATCC cell line Authentification Service, LGC standards, Molsheim, France) and routinely tested for mycoplasma contamination.

Techniques: MANN-WHITNEY, Control, Western Blot, Expressing, Reverse Transcription Polymerase Chain Reaction, Amplification